Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387514 · ClinicalTrials.gov registry record · Phase 2
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03387514 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 5 participants.
The verdict
NCT03387514, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective of this research is to evaluate response to systemic therapy, including anti-angiogenesis therapy and/or immune-based therapies via 18F-DCFPyL prostate-specific membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) in patients with metastatic renal cell carcinoma (RCC) and to compare qualitatively with conventional imaging response criteria - Response Evaluation Criteria In Solid Tumors (RECIST 1.1) and histopathological endpoints including isolation, enumeration and staining of Circulating Tumor Cells (CTC).
Interventions
- DRUG PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-12-08 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03387514
The ClinicalTrials.gov registry entry for NCT03387514 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PSMA-based 18F-DCFPyL PET tracer for PET/CT exams is the first listed.
NCT03387514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03387514 about?
NCT03387514 is a clinical study titled "Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies". The primary objective of this research is to evaluate response to systemic therapy, including anti-angiogenesis therapy and/or immune-based therapies via 18F-DCFPyL prostate-specific membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) in patients with metastatic r...
What is the current status of trial NCT03387514?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-12-08. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT03387514?
The interventions under investigation include: PSMA-based 18F-DCFPyL PET tracer for PET/CT exams (DRUG).
Who is sponsoring clinical trial NCT03387514?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.